BLTE · Belite Bio, Inc · Webcasts, Transcripts & Audio
Market Cap
$6.71B
Shares
40.27M
Volume · Oct 5
85.04K
Avg daily vol (3M)
184.04K
Belite Bio, Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Belite Bio, Inc (BLTE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Earnings call
FY26 · Q2
2026-08-13
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript
Confident tone
NDA submission and FDA path for Stargardt disease
Financial position and operating expenses
Manufacturing and supply readiness
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-20
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Confident tone
NDA submission and FDA approval timeline
Financial position and operating expenses
Dragon 2 / Japan registration trial
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
Confident tone
DRAGON Phase 3 trial results
Prevalence and pediatric expansion
NDA submission and regulatory pathway
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-06-30
Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript
Confident tone
Tinlarebant clinical progress
Geographic atrophy (PHOENIX) trial
Commercialization planning
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript
Confident tone
Phase 3 DRAGON (Stargardt) interim results
Tinlarebant drug profile and safety
PHOENIX Phase 3 trial in geographic atrophy
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Belite Bio, Inc (BLTE) Q4 2024 Earnings Call Transcript
Confident tone
Phase 3 DRAGON trial in Stargardt disease
Enrollment dropout rates
Phase 3 PHOENIX trial in GA
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-19
Belite Bio, Inc (BLTE) Q3 2024 Earnings Call Transcript
Confident tone
Tinlarebant clinical pipeline progress
Phase 2 Stargardt efficacy results
Geographic atrophy positioning vs complement inhibitors
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript
Confident tone
Tinlarebant clinical programs
Japan regulatory strategy
Phase II Stargardt data
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Confident tone
Stargardt disease Phase 2 data
Stargardt Phase 3 (DRAGON) progress
Geographic Atrophy (GA) Phase 3
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Belite Bio, Inc (BLTE) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Belite Bio, Inc (BLTE) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q2
2022-06-30
Belite Bio, Inc (BLTE) Q2 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–15 of 15 webcasts